Agile Therapeutics: No Reason For The FDA To Approve Another Inferior Patch

Company Synopsis

Agile Therapeutics (NASDAQ:AGRX) is a clinical-stage biotech company located in Princeton, New Jersey. It is developing hormonal contraceptive products utilizing Skinfusion for transdermal delivery of drug. The lead product candidate, Twirla, is a combined hormonal contraceptive patch containing 30 micrograms of ethinyl estradiol and levonorgestrel. The current available patch, Xulane (previously Ortho-Evra), contains 35 micrograms of EE but delivers an average dose absorbed into the bloodstream of 20 micrograms/day. Oral contraceptive pills on the market typically contain anywhere from 10-40 micrograms of EE. The lower dose of EE in the patch is thought to translate into a lower amount of EE reaching the bloodstream. However, there have been no head-to-head studies comparing Twirla to Xulane with respect to bioavailability and average daily dose.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.